

## University of Groningen

### Erratum to

Johnson, Martin; Kozielska, Magdalena; Pilla Reddy, Venkatesh; Vermeulen, An; Barton, Hugh A; Grimwood, Sarah; de Greef, Rik; Groothuis, Geny M M; Danhof, Meindert; Proost, Johannes H

*Published in:*  
Pharmaceutical Research

*DOI:*  
[10.1007/s11095-016-1888-2](https://doi.org/10.1007/s11095-016-1888-2)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Johnson, M., Kozielska, M., Pilla Reddy, V., Vermeulen, A., Barton, H. A., Grimwood, S., ... Proost, J. H. (2016). Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D<sub>2</sub> Receptor Occupancy. *Pharmaceutical Research*, 33(5), 1305-1306. <https://doi.org/10.1007/s11095-016-1888-2>

#### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

#### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D<sub>2</sub> Receptor Occupancy

Martin Johnson<sup>1,6</sup> · Magdalena Kozielska<sup>1,7</sup> · Venkatesh Pilla Reddy<sup>1,6</sup> · An Vermeulen<sup>2</sup> · Hugh A. Barton<sup>3</sup> · Sarah Grimwood<sup>3</sup> · Rik de Greef<sup>4</sup> · Geny M. M. Groothuis<sup>1</sup> · Meindert Danhof<sup>5</sup> · Johannes H. Proost<sup>1</sup>

Published online: 10 March 2016

© The Author(s) 2016. This article is published with open access at SpringerLink.com

### Erratum to: Pharm Res

DOI 10.1007/s11095-015-1846-4

There occurred two errors in the above manuscript (Pharm Res. 2015 Dec 30 [Epub ahead of print]). The correct information is as follows:

1) The differential equations in Appendix 2 should read:

$$\begin{aligned}d(A_{bv})/dt &= (CL_{bv}/V_{plasma}) * A_{plasma} - (CL_{bv}/V_{bv}) * A_{bv} - (CL_{d,bv}/V_{bv}) * fu_{plasma} * A_{bv} \\ &+ (CL_{d,bv}/V_{bev}) * fu_{brain} * A_{bev} + (CL_{eff}/V_{bev}) * fu_{brain} * A_{bev} \\d(A_{bev})/dt &= (CL_{d,bv}/V_{bv}) * fu_{plasma} * A_{bv} - (CL_{d,bv}/V_{bev}) * fu_{brain} * A_{bev} - (CL_{eff}/V_{bev}) * fu_{brain} * A_{bev} \\ &- (CL_{st}/V_{bev}) * fu_{brain} * A_{bev} + (CL_{st}/V_{stf}) * fu_{brain} * A_{stf} \\d(A_{stf})/dt &= (CL_{st}/V_{bev}) * fu_{brain} * A_{bev} - (CL_{st}/V_{stf}) * fu_{brain} * A_{stf} - kon * fu_{brain} * A_{stf} * (B_{max} - CB) \\ &+ koff * A_{stb} \\d(A_{stb})/dt &= kon * fu_{brain} * A_{stf} * (B_{max} - CB) - koff * A_{stb}\end{aligned}$$

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11095-015-1846-4>.

✉ Johannes H. Proost  
j.h.proost@rug.nl

- <sup>1</sup> Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
- <sup>2</sup> Clinical Pharmacology & Pharmacometrics, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
- <sup>3</sup> Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut, USA
- <sup>4</sup> Quantitative Solutions, Pivot Park, Molenweg 79, 5349 AC Oss, The Netherlands
- <sup>5</sup> Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden, The Netherlands
- <sup>6</sup> Present address: AstraZeneca, Cambridge, UK
- <sup>7</sup> Present address: Institute of Engineering, Hanze University of Applied Sciences, Assen, The Netherlands

2) Table III should read:

**Table III** *In vitro*, *in vivo* and *ex vivo* values estimates used in the human D<sub>2</sub>RO predictive model.

	Clozapine	Haloperidol	Olanzapine	Paliperidone	Quetiapine	Risperidone
Fraction unbound in brain	0.011 <sup>a</sup>	0.023 <sup>b</sup>	0.034 <sup>a</sup>	0.0755 <sup>c</sup>	0.025 <sup>a</sup>	0.0699 <sup>c</sup>
Fraction unbound in plasma	0.0300 <sup>d</sup>	0.0800 <sup>e</sup>	0.0700 <sup>m</sup>	0.226 <sup>f</sup>	0.170 <sup>e</sup>	0.100 <sup>f</sup>
Approach A: Human D <sub>2</sub> RO predictions based on <i>in vitro</i> information						
Papp × 10 <sup>-6</sup> (cm/s)	28.3 <sup>a</sup>	28.6 <sup>a</sup>	15.7 <sup>a</sup>	16.8 <sup>g</sup>	33.0 <sup>a</sup>	19.8 <sup>g</sup>
CL <sub>be<sub>v</sub></sub> (L/h) derived from Papp	20.4	20.6	11.3	7.80	23.8	12.96
Efflux ratio	–	–	–	2.10 <sup>g</sup>	–	1.20 <sup>g</sup>
CL <sub>eff</sub> (L/h) based on ER	–	–	–	8.58	–	2.59
<i>In vitro</i> Ki (nM)	82.0 <sup>h</sup>	0.700 <sup>h</sup>	5.10 <sup>i</sup>	2.075 <sup>e</sup>	155 <sup>h</sup>	2.175 <sup>e</sup>
k <sub>off</sub> (h <sup>-1</sup> )	83.16 <sup>h</sup>	1.02 <sup>h</sup>	2.34 <sup>h</sup>	1.56 <sup>j,n</sup>	180.78 <sup>h</sup>	1.56 <sup>j</sup>
Approach B: Human D <sub>2</sub> RO predictions based on <i>in vivo</i> information						
Papp <sub>calc</sub> × 10 <sup>-6</sup> (cm/s)	–	–	100	493 <sup>n</sup>	–	493
CL <sub>be<sub>v</sub></sub> (L/h) based on Papp <sub>calc</sub>	–	–	72.2	355 <sup>n</sup>	–	355
CL <sub>eff</sub> (L/h) scaled from rat	–	–	NA	11594	–	2486
k <sub>off</sub> (h <sup>-1</sup> )	–	–	3.04 <sup>k</sup>	0.671 <sup>l,n</sup>	–	0.671 <sup>l</sup>
Approach C: Human D <sub>2</sub> RO predictions integrating <i>in vitro</i> and <i>in vivo</i> information						
Corrected <i>In vivo</i> Kd (nM)	–	–	4.38	0.352	–	0.395

NA Not applicable

<sup>a</sup> Reference (32); <sup>b</sup> Reference (33); <sup>c</sup> Reference (34); <sup>d</sup> Reference (35); <sup>e</sup> In-house values; <sup>f</sup> Reference (36); <sup>g</sup> Reference (37);

<sup>h</sup> Reference (38); <sup>i</sup> Reference (39); <sup>j</sup> Reference (5); <sup>k</sup> Reference (7); <sup>l</sup> Reference (8); <sup>m</sup> Reference (40); <sup>n</sup> Assumed to be equal to risperidone